ProCE Banner Activity

HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer

Slideset Download
Conference Coverage
In patients with HER2+ MBC and previous treatment with trastuzumab, pertuzumab, and T-DM1, tucatinib in combination with trastuzumab and capecitabine substantially extended survival outcomes compared with trastuzumab and capecitabine alone, including in patients with brain metastases.

Released: December 16, 2019

Expiration: December 14, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen